Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Min Shu

Dong-Ming Shen

Zhicai Wu

Hong Shen

Peter J Sinclair

Richard Thomas Beresis

Anthony K Ogawa

Robert J DeVita

Yuguang Wang

Ping Lan

Changhe Qi

Alejandro Crespo

John Qiang Tan

Zhongxiang Sun

Rudrajit Mal

Ellen K Vande Bunte

Sander G Mills

Kun Liu

Jeffrey John Hale

Jinlong Jiang

Thomas H Graham

Kevin Tyler Chapman

Zhi-Cai Shi

Christopher Alan Willoughby

Cangming Yang

Keith Rosauer

Robert J Devita

The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.

Mineralocorticoid receptor antagonists

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. 

Prolylcarboxypeptidase inhibitors

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too. 

Compounds of structural formula (I) are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. 

Pyrrolidine modulators of CCR5 chemokine receptor activity

Growing community of inventors

Green Brook, NJ, United States of America

Min Shu